Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Adult cystic hygroma: successful use of OK-432 (Picibanil®)

  • S L Woolley, D R K Smith, S Quine
  • Journal:
    The Journal of Laryngology & Otology / Volume 122 / Issue 11 / November 2008
    Published online by Cambridge University Press:
    23 April 2008, pp. 1260-1264
    Print publication:
    November 2008
  • Objective:

    We report an adult case of cystic lymphangioma treated with OK-432 (Picibanil®).

    Method:

    A case report and review of the literature concerning the use of OK-432 to treat cystic lymphangioma is presented.

    Results:

    A 31-year-old woman developed a cystic lymphangioma four weeks post-partum. This was treated initially by aspiration, for diagnostic purposes. Investigation suggested that surgery would be challenging. A review of the literature demonstrated success with OK-432 in the treatment of this condition, although primarily in the paediatric population. This patient was successfully treated thus, and at the time of writing remained symptom free. A suggested management plan is outlined.

    Conclusion:

    Treatment with OK-432 is useful in the management of cystic lymphangiomas in adults and should be considered as first line treatment.